Trial Outcomes & Findings for Supportive and Supportive-Expressive Treatment for Depression (NCT NCT02728557)

NCT ID: NCT02728557

Last Updated: 2025-01-27

Results Overview

A clinically administered measure assessing the severity of depression. The Hamilton is the standard measure of depression severity for clinical trials. The scoring is based on the first 17-items of the Hamilton. 0-7 = NORMAL 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression \>=23 = Very Severe Depression Hamilton Rating Scale for Depression, developed by Max Hamilton in 1967, is a widely used tool for assessing the severity of depression in adults. 17 items covering various aspects of depression experienced in the past week. Each item is rated on a 3-point or 5-point scale depending on the specific symptom. Total score (sum score) provides an indication of depression severity. The range is 0-52

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

100 participants

Primary outcome timeframe

Slope from baseline to week 16.

Results posted on

2025-01-27

Participant Flow

Participant milestones

Participant milestones
Measure
Supportive-expressive Psychotherapy
Participants will receive supportive-expressive therapy. Supportive-Expressive Therapy: Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
Supportive Psychotherapy
Participants will receive supportive therapy. Supportive Therapy: Supportive psychotherapy for depressive disorder for 16 weeks.
Overall Study
STARTED
50
50
Overall Study
COMPLETED
48
45
Overall Study
NOT COMPLETED
2
5

Reasons for withdrawal

Reasons for withdrawal
Measure
Supportive-expressive Psychotherapy
Participants will receive supportive-expressive therapy. Supportive-Expressive Therapy: Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
Supportive Psychotherapy
Participants will receive supportive therapy. Supportive Therapy: Supportive psychotherapy for depressive disorder for 16 weeks.
Overall Study
Dissatisfaction with assigned treatment
1
3
Overall Study
Dissatisfaction with research tasks
0
1
Overall Study
Scheduling or change in availability
1
1

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Supportive Psychotherapy
n=50 Participants
Participants will receive supportive therapy. Supportive Therapy: Supportive psychotherapy for depressive disorder for 16 weeks.
Supportive-expressive Psychotherapy
n=50 Participants
Participants will receive supportive-expressive therapy. Supportive-Expressive Therapy: Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
Total
n=100 Participants
Total of all reporting groups
Age, Continuous
31.02 Years
STANDARD_DEVIATION 6.9 • n=50 Participants
31.5 Years
STANDARD_DEVIATION 9.6 • n=50 Participants
31.2 Years
STANDARD_DEVIATION 8.25 • n=100 Participants
Sex: Female, Male
Female
29 Participants
n=50 Participants
28 Participants
n=50 Participants
57 Participants
n=100 Participants
Sex: Female, Male
Male
21 Participants
n=50 Participants
22 Participants
n=50 Participants
43 Participants
n=100 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
Israel
50 participants
n=50 Participants
50 participants
n=50 Participants
100 participants
n=100 Participants
HRSD
20.84 Unit on a scale
STANDARD_DEVIATION 3.588 • n=50 Participants
21.00 Unit on a scale
STANDARD_DEVIATION 3.881 • n=50 Participants
20.92 Unit on a scale
STANDARD_DEVIATION 3.719 • n=100 Participants

PRIMARY outcome

Timeframe: Slope from baseline to week 16.

A clinically administered measure assessing the severity of depression. The Hamilton is the standard measure of depression severity for clinical trials. The scoring is based on the first 17-items of the Hamilton. 0-7 = NORMAL 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression \>=23 = Very Severe Depression Hamilton Rating Scale for Depression, developed by Max Hamilton in 1967, is a widely used tool for assessing the severity of depression in adults. 17 items covering various aspects of depression experienced in the past week. Each item is rated on a 3-point or 5-point scale depending on the specific symptom. Total score (sum score) provides an indication of depression severity. The range is 0-52

Outcome measures

Outcome measures
Measure
Supportive-expressive Psychotherapy
n=50 Participants
Participants will receive supportive-expressive therapy. Supportive-Expressive Therapy: Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
Supportive Psychotherapy
n=50 Participants
Participants will receive supportive therapy. Supportive Therapy: Supportive psychotherapy for depressive disorder for 16 weeks.
Hamilton Rating Scale for Depression (HRSD)
Change from baseline to week 16
12.32 units on a scale
Standard Deviation 6.52
12.06 units on a scale
Standard Deviation 6.26
Hamilton Rating Scale for Depression (HRSD)
Baseline
20.20 units on a scale
Standard Deviation 4.106
20.08 units on a scale
Standard Deviation 3.702

SECONDARY outcome

Timeframe: Slope from baseline to week 16. Measured at baseline, every week for 16 weeks of treatment, then once a month for four months and follow up after a year; Scores are provided for baseline and change from baseline to week 16

Beck Depression Inventory; measuring depression by a self-report measure; higher means worse outcomes. The Beck Depression Inventory consists of 21 multiple-choice questions. Each question presents different statements reflecting varying intensities of a particular depressive symptom. Each question has scores ranging from 0 (no symptoms) to 3 (most severe symptoms). The total score is obtained by summing up the scores of all chosen responses. Based on the total score, there are different interpretations of depression severity: Scores in the 0-13 range suggest minimal or no depression. Scores between 14-19 indicate mild depression. Scores from 20-28 reflect moderate depression. Scores 29 and above suggest severe depression. Range 0-63

Outcome measures

Outcome measures
Measure
Supportive-expressive Psychotherapy
n=50 Participants
Participants will receive supportive-expressive therapy. Supportive-Expressive Therapy: Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
Supportive Psychotherapy
n=50 Participants
Participants will receive supportive therapy. Supportive Therapy: Supportive psychotherapy for depressive disorder for 16 weeks.
Beck Depression Inventory (BDI)
Change from baseline to week 16
16.62 units on a scale
Standard Deviation 9.63
13.36 units on a scale
Standard Deviation 10.59
Beck Depression Inventory (BDI)
Baseline
27.55 units on a scale
Standard Deviation 8.617
25.76 units on a scale
Standard Deviation 7.604

SECONDARY outcome

Timeframe: Slope from baseline to week 16. Measured at baseline, every week for 16 weeks of treatment, then once a month for four months and follow up after a year; Scores are provided for baseline and change from baseline to week 16

Outcome Questionnaire; measuring Symptom Distress, Interpersonal Relationships, Social Role; higher levels mean worse outcome. Outcome Questionnaire-30 (OQ-30; Lambert et al., 1996). OQ-30 is a 30-item self-report measure assessing distress, designed to measure patient progress. Items were rated on a 5 point likert scale ranging from 0 (never) to 4 (almost always). The OQ-30 has three subscales assessing symptom distress, interpersonal relations, and social role performance. A total score is calculated by sum scores. Range 0-120

Outcome measures

Outcome measures
Measure
Supportive-expressive Psychotherapy
n=50 Participants
Participants will receive supportive-expressive therapy. Supportive-Expressive Therapy: Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
Supportive Psychotherapy
n=50 Participants
Participants will receive supportive therapy. Supportive Therapy: Supportive psychotherapy for depressive disorder for 16 weeks.
Outcome Questionnaire (OQ)
Changes from baseline to week 16
32.26 units on a scale
Standard Deviation 20.54
26.33 units on a scale
Standard Deviation 18.44
Outcome Questionnaire (OQ)
Baseline
73.435 units on a scale
Standard Deviation 13.504
69.519 units on a scale
Standard Deviation 13.213

OTHER_PRE_SPECIFIED outcome

Timeframe: Measured at baseline, six times during the treatment (weeks 1, 2, 4, 8, 12, 16), then once a month for four months and follow up after a year; reports refer to baseline and changes from baseline to week 16

Inventory of Interpersonal Problems Circumplex; measuring interpersonal problems; higher means worse outcomes Inventory of Interpersonal Problems-Circumplex (IIP-C). The IIP-C is a 32-item self-report questionnaire assessing interpersonal difficulties and distress. Patients rate two types of items: interpersonal behaviors that are "hard for you to do" (e.g., "it is hard for me to let other people know when I am angry") and interpersonal behaviors that "you do too much" (e.g., "I am too afraid of other people"). Ratings of the degree to which each problem is distressing are made on a 5-point scale, ranging from 0 (not at all) to 4 (extremely). Calculated as a sum score. Range 0 -128

Outcome measures

Outcome measures
Measure
Supportive-expressive Psychotherapy
n=50 Participants
Participants will receive supportive-expressive therapy. Supportive-Expressive Therapy: Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
Supportive Psychotherapy
n=50 Participants
Participants will receive supportive therapy. Supportive Therapy: Supportive psychotherapy for depressive disorder for 16 weeks.
Inventory of Interpersonal Problems Circumplex (IIP-C)
Changes from baseline to week 16
13.38 units on a scale
Standard Deviation 15.92
11.94 units on a scale
Standard Deviation 12.7
Inventory of Interpersonal Problems Circumplex (IIP-C)
Baseline
55.58 units on a scale
Standard Deviation 12.52
59.32 units on a scale
Standard Deviation 15.306

OTHER_PRE_SPECIFIED outcome

Timeframe: Measured at baseline, six times during the treatment (weeks 1, 2, 4, 8, 12, 16), then once a month for four months and follow up after a year; reports refer to baseline and changes from baseline to week 16

Experiences in Close Relationships Questionnaire; The measurement data will be aggregated into two sub-scales: anxiety and avoidance; higher scores mean worse outcomes (less secure attachment) Experience in Close Relationships Scale (ECR; Brennan et al., 1998). 36-item self-reported measure. Participants rated the extent to which each item was descriptive of their experiences in close relationships on a 7-point Likert scale ranging from 1 (not at all) to 7 (very much). 18 items assessed attachment anxiety (e.g., "I worry about being abandoned"). 18 assessed attachment avoidance (e.g., "I prefer not to show a partner how I feel deep down"). The reliability and validity of these scales have been repeatedly demonstrated (Brennan et al., 1998; Mikulincer \& Shaver, 2007). The score for each subscale is calculated as the average value Range 1-7

Outcome measures

Outcome measures
Measure
Supportive-expressive Psychotherapy
n=50 Participants
Participants will receive supportive-expressive therapy. Supportive-Expressive Therapy: Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
Supportive Psychotherapy
n=50 Participants
Participants will receive supportive therapy. Supportive Therapy: Supportive psychotherapy for depressive disorder for 16 weeks.
Experiences in Close Relationships Questionnaire (ECR)
Anxiety - change from baseline to week 16
0.9 units on a scale
Standard Deviation 1.16
0.6 units on a scale
Standard Deviation 0.97
Experiences in Close Relationships Questionnaire (ECR)
Avoidance - change from baseline to week 16
0.54 units on a scale
Standard Deviation 0.87
0.21 units on a scale
Standard Deviation 0.79
Experiences in Close Relationships Questionnaire (ECR)
Anxiety - baseline
4.07 units on a scale
Standard Deviation 1.207
4.101 units on a scale
Standard Deviation 1.02
Experiences in Close Relationships Questionnaire (ECR)
Avoidance - baseline
4.202 units on a scale
Standard Deviation 1.045
4.036 units on a scale
Standard Deviation 1.011

OTHER_PRE_SPECIFIED outcome

Timeframe: Measured at baseline, six times during the treatment (weeks 1, 2, 4, 8, 12, 16), then once a month for four months and follow up after a year; reports refer to baseline and change from baseline to week 16

Quality of Life Enjoyment and Satisfaction- Short Version; measuring quality of life; higher scores mean better outcomes. The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). It's a self-report measure, meaning the person being assessed completes the questionnaire themselves. Purpose: It gauges the degree of enjoyment and satisfaction a person experiences in different areas of their daily functioning. Utilize a 5-point Likert scale, ranging from 1 (very poor) to 5 (very good). Higher scores mean better outcomes. Range 1-5. Average score

Outcome measures

Outcome measures
Measure
Supportive-expressive Psychotherapy
n=50 Participants
Participants will receive supportive-expressive therapy. Supportive-Expressive Therapy: Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
Supportive Psychotherapy
n=50 Participants
Participants will receive supportive therapy. Supportive Therapy: Supportive psychotherapy for depressive disorder for 16 weeks.
Quality of Life Enjoyment and Satisfaction- Short Version (Q-LES-Q)
Change from baseline to week 16
0.70 units on a scale
Standard Deviation 0.73
0.48 units on a scale
Standard Deviation 0.63
Quality of Life Enjoyment and Satisfaction- Short Version (Q-LES-Q)
Baseline
2.848 units on a scale
Standard Deviation 0.542
2.801 units on a scale
Standard Deviation 0.505

Adverse Events

Supportive-expressive Psychotherapy

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Supportive Psychotherapy

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Prof. Sigal Zilcha-Mano

University of Haifa

Phone: 972-4-8249047

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place